Skip to main contentSkip to navigation
Sirius Investors

TCF.L Stock: Theracryf Plc Stock Price, Analysis & Insights

Get live TCF.L stock price $0.25, comprehensive Theracryf Plc stock analysis, charts, news, and expert forecast. Real-time TCF.L stock data and investment insights.

0.25
4.17%Today
TCF.LTheracryf Plc • London Stock Exchange • Healthcare
Market Cap
5.37M
Volume
387.31K
52W High
0.30
52W Low
0.17

Loading chart data...

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Theracryf Plc operates as a clinical-stage biotechnology firm, dedicated to advancing treatments for oncological diseases and various brain disorders affecting behavior. Its primary therapeutic asset, SFX-01, is currently progressing through Phase II...

Company Information

CEO
Huw Jones
Sector
Healthcare
Industry
Biotechnology
Employees
9

Contact Information

Address
Alderley Park
Country
GB

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Higher growth potential with elevated volatility (Beta: 1.40)

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Theracryf Plc shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Theracryf Plc
  • Investors should consider how Theracryf Plc fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

5.37M

P/E Ratio (TTM)

-0.25

Beta

1.40

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

51/100 ⭐⭐⭐

Overall
-0.5%
NYSE
-0.9%
NASDAQ
+0.0%
Sector1D1W1MP/EScore
Financial Services+0.7%+1.6%+2.3%20.0
87/100⭐⭐⭐⭐⭐
Technology+1.0%+1.3%+3.2%52.1
78/100⭐⭐⭐⭐⭐
Basic Materials+0.8%+0.2%+1.9%27.9
65/100⭐⭐⭐⭐
Industrials-0.0%-0.7%+3.0%43.2
64/100⭐⭐⭐⭐
Communication Services-0.3%-0.8%+0.9%22.0
53/100⭐⭐⭐
Healthcare-0.5%-1.4%+2.1%30.5
51/100⭐⭐⭐
Consumer Defensive+0.2%+1.1%-3.0%31.1
37/100⭐⭐
Energy+1.4%-2.8%+0.8%36.3
35/100⭐⭐
Real Estate+0.3%-1.3%-0.3%50.0
30/100⭐⭐
Utilities+1.0%-2.2%-6.0%26.1
26/100⭐⭐
Consumer Cyclical-0.9%-0.3%-0.7%54.7
24/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-06-12.